BioPharmSignal logoBioPharmSignal

Biotech News

C4 Therapeutics to Participate in Upcoming November Investor Conferences

C4 Therapeutics (CCCC)C4 TherapeuticsCompany update

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in upcoming investor conferences in November.

Related news

RLAYRelay Therapeutics2026-11-02 21:05 EST

Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November

CCCCC4 Therapeutics2026-11-02 21:01 EST

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CCCCC4 Therapeutics2026-10-29 11:00 EST

C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders

CMPXCompass Therapeutics2026-11-02 14:00 EST

Compass Therapeutics to Participate in Upcoming November Investor Events

FATEFate Therapeutics2026-10-01 11:00 EST

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

MGNXMacroGenics2026-11-05 21:05 EST

MacroGenics to Participate in Upcoming Investor Conferences

STROSutro Biopharma2026-11-04 13:00 EST

Sutro Biopharma to Participate in Upcoming Investor Conferences

ANGOAngioDynamics2026-10-29 12:00 EST

AngioDynamics to Participate in Upcoming Investor Conferences

RVMDRevolution Medicines2026-10-27 20:05 EST

Revolution Medicines to Participate in November 2026 Investor Conferences

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

View all latest news

C4 Therapeutics

Targeted Protein Degradation Company C4 Therapeutics develops medicines that use the cell’s protein-disposal machinery to remove disease-causing proteins. Cemsidomide Cemsidomide is an oral molecular glue degrader of IKZF1 and IKZF3 being developed as a potential foundational therapy for multiple myeloma. Combination Strategy Clinical...

Recent company news

CCCCC4 Therapeutics2026-11-03 12:00 EST

C4 Therapeutics to Participate in Upcoming November Investor Conferences

CCCCC4 Therapeutics2026-11-02 21:01 EST

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CCCCC4 Therapeutics2026-10-29 11:00 EST

C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders

CCCCC4 Therapeutics2026-09-25 11:00 EST

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

CCCCC4 Therapeutics2026-09-03 11:00 EST

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting

Stock data

Close
2.95 USD
Market cap
479.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States